Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
18 hedge funds and large institutions have $1.43M invested in Iterum Therapeutics in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
88% more capital invested
Capital invested by funds: $762K → $1.43M (+$669K)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
13% more funds holding
Funds holding: 16 → 18 (+2)
4.04% more ownership
Funds ownership: 2.88% → 6.92% (+4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$705K |
| 2 |
Renaissance Technologies
New York
|
+$98.2K |
| 3 |
Millennium Management
New York
|
+$45.6K |
| 4 |
AF
Apollon Financial
Mount Pleasant,
South Carolina
|
+$40.2K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$24.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$34.5K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$16.1K |
| 3 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$197 |
| 4 |
CCMW
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
|
-$130 |
ITRM Hedge Fund Activity: Q1 2024 in Review
18 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q1 2024, worth a combined $1.43M — up 88% from $762K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ITRM positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $705K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $34.5K sold.
- 18 institutional investors held Iterum Therapeutics (ITRM) as of Q1 2024, up from 16 in Q4 2023.
- Funds reported $1.43M of Iterum Therapeutics stock for Q1 2024, up 88% quarter-over-quarter.
- 5 funds opened new Iterum Therapeutics positions in Q1 2024 and 3 closed out, a net change of +2 holders.
- The largest Iterum Therapeutics buyer in Q1 2024 was Point72 Asset Management, an estimated $705K added.
- The largest Iterum Therapeutics seller in Q1 2024 was Susquehanna International Group, an estimated $34.5K sold.
Based on aggregated 13F filings for Q1 2024.